As a company, Gilead is uniquely positioned to accelerate progress in the fight against HIV/AIDS in Asia.
Founded in the San Francisco Bay area, one of the epicenters of the initial HIV/AIDS outbreak, we have witnessed first-hand the devastation HIV/AIDS causes in communities around the world. At the same time, Gilead is a leading innovator in the field of HIV, making a significant impact in transforming and simplifying care for people with HIV/AIDS.
The Joint United Nations Program on HIV or UNAIDS has set ambitious targets as a crucial step in ending the AIDS epidemic by 2030. These targets, also known as the 95-95-95 fast-track targets, aim to diagnose 95% of all HIV-positive persons, provide treatment for 95% of those diagnosed, and achieve viral suppression for 95% of those treated.
At Gilead, we remain committed through our science, therapies and funding to support communities in Asia and around the world to reach these targets.
In this spirit, in 2018, we launched the Gilead Asia Pacific Rainbow Grant program to focus on supporting diverse, impactful, and sustainable community-based projects that empower underserved communities that experience obstacles to care. To learn more about Rainbow Grantee projects that support HIV-affected communities across Asia Pacific, click here.
Through our grant program, Gilead wants to support projects that place people at the center of care.
Our grant program aims to empower people living with HIV and persons-at-risk to achieve the best quality of life possible.
Our grant program aims to engage communities on quality-of-life topics for people living with HIV and persons-at-risk, ultimately resulting in societies that are free of judgment and stigma.
Partnerships and alliances among communities, NGOs, governments, and businesses are important as we work on HIV programs that help people with HIV and persons-at-risk live long and healthy